Want to see ELVN full AI Analyst Report?
ELVN Stock Chart & Stats
$60.50
$0.14(0.27%)
At close: 4:00 PM EDT
$60.50
$0.14(0.27%)
Day’s Range― - ―
52-Week Range$14.79 - $62.32
Previous Close$53
Volume368.77K
Average Volume (3M)1.60M
Market Cap
$3.04B
Enterprise Value$2.46B
Total Cash (Recent Filing)$895.15M
Total Debt (Recent Filing)$1.51M
Price to Earnings (P/E)―
Beta0.90
Next Earnings
Nov 18, 2026EPS Estimate
-0.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.64
Shares Outstanding73,270,760
10 Day Avg. Volume1,581,338
30 Day Avg. Volume1,595,343
Financial Highlights & Ratios
PEG Ratio2.65
Price to Book (P/B)1.90
Price to Sales (P/S)0.00
P/FCF Ratio-12.38
Enterprise Value/Market Cap0.81
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-41.08K
Enterprise Value/Ebitda-23.29
Forecast
1Y Price Target
$74.33Price Target Upside22.87% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-1.86
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageMinimal debt relative to the equity base reduces solvency and interest-burden risk while giving Enliven greater flexibility to fund research and development. This capitalization can provide more resilience through clinical milestones, although it does not remove the need for future financing.
Substantially Stronger CapitalizationThe substantial increase in total assets indicates a materially larger capital base supporting Enliven’s clinical-development strategy. Greater capitalization can extend operational capacity and help fund pivotal programs, providing a durable foundation even though the company remains pre-commercial.
Experienced Biotech GovernanceAdding an experienced biopharmaceutical executive to the board and Audit Committee strengthens governance and financial oversight. Her clinical-to-commercial background is particularly relevant as Enliven prepares the ENABLE-2 pivotal Phase 3 trial and evaluates the longer-term path toward commercialization.
Bears Say
Pre-commercial Business ModelThe absence of product revenue means Enliven has not yet demonstrated commercial monetization and must fund its business before establishing a recurring revenue base. Its outlook therefore remains dependent on successful clinical development, regulatory progress, and eventual market adoption.
Large And Persistent LossesLosses have expanded substantially from earlier periods and remain deeply negative on a trailing basis, showing that operating investment is not yet producing earnings. Persistent losses reduce internal funding capacity and increase dependence on clinical success and continued access to capital.
Ongoing Cash BurnNegative operating and free cash flow show that research and operations consume cash rather than generate it. Continued burn can require additional external financing before commercialization, creating funding dependency and potential pressure on future capital allocation while development programs advance.
Enliven Therapeutics News
ELVN FAQ
What was Enliven Therapeutics’s price range in the past 12 months?
Enliven Therapeutics lowest stock price was $14.79 and its highest was $62.32 in the past 12 months.
What is Enliven Therapeutics’s market cap?
Enliven Therapeutics’s market cap is $3.04B.
When is Enliven Therapeutics’s upcoming earnings report date?
Enliven Therapeutics’s upcoming earnings report date is Nov 18, 2026 which is in 23 days.
How were Enliven Therapeutics’s earnings last quarter?
Enliven Therapeutics released its earnings results on Aug 05, 2026. The company reported -$0.49 earnings per share for the quarter, missing the consensus estimate of -$0.387 by -$0.103.
Is Enliven Therapeutics overvalued?
According to Wall Street analysts Enliven Therapeutics’s price is currently Undervalued.
Does Enliven Therapeutics pay dividends?
Enliven Therapeutics does not currently pay dividends.
What is Enliven Therapeutics’s EPS estimate?
Enliven Therapeutics’s EPS estimate is -0.45.
How many shares outstanding does Enliven Therapeutics have?
Enliven Therapeutics has 73,270,760 shares outstanding.
What happened to Enliven Therapeutics’s price movement after its last earnings report?
Enliven Therapeutics reported an EPS of -$0.49 in its last earnings report, missing expectations of -$0.387. Following the earnings report the stock price went up 0.955%.
Which hedge fund is a major shareholder of Enliven Therapeutics?
Currently, no hedge funds are holding shares in ELVN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Enliven Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$74.33 (22.87% Upside)
$74.33 (22.87% Upside)
Blogger Sentiment
Bullish
ELVN Sentiment 75%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Increased
By 261.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 1.6%
Last 30 Days ▼ 1.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
102.04%
12-Months-Change
Fundamentals
Return on Equity
-18.55%
Trailing 12-Months
Asset Growth
80.64%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Enliven Therapeutics
Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene. The company's base of operations is located in Boulder, Colorado.
ELVN Stock 12 Month Forecast
Average Price Target
$74.33
▲(22.87% Upside)
Technical Analysis
Crispr Therapeutics AG
―
IDEAYA Biosciences
―
Legend Biotech
―
Relay Therapeutics
―
Tango Therapeutics
―
Ownership Overview
22.50% Insiders
13.90% Mutual Funds
1.81% Other Institutional Investors
49.94% Public Companies and
Individual Investors